NCT01809912View on ClinicalTrials.gov

Safety Study of MG1102 in Patients With Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Solid Tumors
Interventions
DRUG

Recombinant human apolipoprotein(a) Kringle V

Trial Locations (1)

120-752

Yonsei Cancer Center, Yonsei University Severance Hospital, Seoul

Sponsors

Collaborators (1)

ICON Clinical Research
All Listed Sponsors
collaborator

ICON Clinical Research

INDUSTRY

lead

Green Cross Corporation

INDUSTRY